SHL Telemedicine Ltd. (SHLTN.SW)
- Previous Close
4.6100 - Open
4.8400 - Bid 4.6000 x --
- Ask 5.1000 x --
- Day's Range
4.8400 - 4.8500 - 52 Week Range
4.5000 - 11.5000 - Volume
277 - Avg. Volume
6,245 - Market Cap (intraday)
79.505M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5700 - Earnings Date Apr 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 10, 2019
- 1y Target Est
--
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. It offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. The company serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was founded in 1987 and is headquartered in Tel Aviv, Israel.
www.shl-telemedicine.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SHLTN.SW
Performance Overview: SHLTN.SW
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHLTN.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHLTN.SW
Valuation Measures
Market Cap
75.57M
Enterprise Value
82.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.45
Price/Book (mrq)
1.49
Enterprise Value/Revenue
1.45
Enterprise Value/EBITDA
10.20
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.36%
Return on Assets (ttm)
-5.03%
Return on Equity (ttm)
-10.10%
Revenue (ttm)
57.08M
Net Income Avi to Common (ttm)
-7.06M
Diluted EPS (ttm)
-0.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
26.25M
Total Debt/Equity (mrq)
25.97%
Levered Free Cash Flow (ttm)
-5.32M